Shares of Quince Therapeutics, Inc. (NASDAQ: 
QNCX) saw a noteworthy uptick of over 300% in Tuesdays extended trading it went further to extend gains to Wednesday premarket as the shares are up another 53% eyeing the $2 pivot amidst bullish sentiment.
The shares soared because the company has engaged LifeSci Capital to serve as its exclusive financial advisor.
This strategic move has spurred the stock some 300% higher Tuesday afternoon, with volume exceeding 1.1 billion shares.
Quince Therapeutics announced recently that it has engaged LifeSci Capital to explore strategic alternatives aimed at maximizing shareholder value, including potential partnerships and restructuring of the company's liabilities.
Options on the table include partnerships, joint ventures, mergers, acquisitions, licensing deals or other transactions, and LifeSci will also advise on any restructuring of the company's liabilities.
Albeit current sporadic surge of over 300%, according to 3 analysts, the average rating forQNCX stock is "Hold." The 12-month stock price target is $10.0, which is an increase of 1,795.02% from the latest price.
About QNCX
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
QNCX) saw a noteworthy uptick of over 300% in Tuesdays extended trading it went further to extend gains to Wednesday premarket as the shares are up another 53% eyeing the $2 pivot amidst bullish sentiment.The shares soared because the company has engaged LifeSci Capital to serve as its exclusive financial advisor.
This strategic move has spurred the stock some 300% higher Tuesday afternoon, with volume exceeding 1.1 billion shares.
Quince Therapeutics announced recently that it has engaged LifeSci Capital to explore strategic alternatives aimed at maximizing shareholder value, including potential partnerships and restructuring of the company's liabilities.
Options on the table include partnerships, joint ventures, mergers, acquisitions, licensing deals or other transactions, and LifeSci will also advise on any restructuring of the company's liabilities.
Albeit current sporadic surge of over 300%, according to 3 analysts, the average rating for
QNCX stock is "Hold." The 12-month stock price target is $10.0, which is an increase of 1,795.02% from the latest price.About QNCX
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.